

Reconsideration of this application and pending claims in view of the amendments and discussion below is respectfully requested.

IN THE CLAIMS

Please cancel claims 19, 25 and 33.

Please enter the amended claims 1, 6, 7, 18, 20, 21, 26 and 27 below, the amendments of which are provided in Appendix I.

C1 1. (Amended) A method for conferring resistance to endotoxic shock, comprising administering to an animal a composition having a physiologically effective amount of at least one OB-R agonist ligand.

C2 6. (Amended) The method of claim 1 wherein the endotoxic shock occurs in sepsis.

7. (Amended) The method of claim 1 wherein the endotoxic shock occurs in systemic inflammatory response syndrome.

18. (Twice Amended) A method for the treatment of a patient having obesity comprising the steps of:

C3 administering at least one compound capable of inducing OB-R expression selected from the group consisting of LPS, IL-1 $\alpha$ , IL-1 $\beta$ , TNF- $\alpha$  and IL-6; and

administering a physiologically effective amount of an OB-R agonist ligand.

20. (Amended) The method of claim 18 wherein the compound and the OB-R agonist ligand are administered at different times.

C4 21. (Amended) The method of claim 18 wherein the compound is administered in an amount from about 0.003 to about 20 micrograms per kilogram body weight.

26. (Amended) The method of claim 18 wherein IL-6 is administered in an amount from about 0.5 to about 20 micrograms per kilogram body weight.

C5 27. (Twice Amended) A method for inducing OB receptor expression in an animal, comprising